Vanessa Gonzalez

California University of Pennsylvania — United States

Medicine · Health Sciences

24h-index11.9kcitations133works16.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(84), Acute Lymphoblastic Leukemia research(42), Immunotherapy and Immune Responses(12), Virus-based gene therapy research(9), Immune Cell Function and Interaction(9)

Publications133 total

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.
2026Open Access
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
Nature Medicine·2026
Phase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers
Molecular Therapy·2026
Utilizing the dynamic gastrointestinal model (DGM) to evaluate the gastric integrity of Capsugel® Enprotect® capsules in fasted and fed states
European Journal of Pharmaceutics and Biopharmaceutics·2025Open Access
Tackling Barriers To Increase Early Palliative Care Access For Older Adults
Innovation in Aging·2025Open Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia
Blood·2025
Abstract Sat702: Increasing Biomarkers of Systemic Inflammation after Pediatric Cardiac Arrest are Associated with Hospital Mortality: A Preliminary Report from a Prospective Cohort Study
Circulation·2025
IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia
Blood·2025Open Access
CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL
Blood·2025Open Access
Abstract 4362152: Preoperative Blood Biomarkers Outperform Clinical Variables in Predicting Poor Outcome After Neonatal Cardiopulmonary Bypass Surgery
Circulation·2025
CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia
Blood·2025
Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy:  preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial
Blood·2025
Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE)  are caused by CD4+ CAR T-cells
Blood·2025
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
Nature Biomedical Engineering·2025· 1 cited
CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer
Cell Reports Medicine·2025· 2 citedOpen Access
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
Nature Medicine·2025· 3 citedOpen Access
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
Nature Medicine·2025· 38 citedOpen Access
A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).
Journal of Clinical Oncology·2025· 4 cited
page 1 of 7Next →

Frequent Co-authors

Carl H. June(42), Simon F. Lacey(29), Joseph A. Fraietta(26), J. Joseph Melenhorst(24), Bruce L. Levine(22), Gabriela Plesa(22), Shannon L. Maude(17), Stephan A. Grupp(17), Wei‐Ting Hwang(17), Julie K. Jadlowsky(16), Elizabeth O. Hexner(15), Anne Chew(14), Noelle V. Frey(13), Edward A. Stadtmauer(13), Don L. Siegel(13), Adam D. Cohen(12), Richard Aplenc(11), David M. Barrett(11), David T. Teachey(11), Michael C. Milone(11)